Teenagers with type 1 diabetes now have the first randomized trial evidence that an SGLT2 inhibitor can protect their kidneys ...
The euglycemic diabetic ketoacidosis (DKA) that has recently been associated with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors will probably turn out to be very infrequent in patients ...
Many cases of sodium-glucose cotransporter-2 (SGLT2) inhibitor-associated diabetic ketoacidosis (DKA) are preventable, new research suggests. But physicians and patients are missing the signs and ...
The FDA said it had received 20 reports in the 15 months since the first of the SGLT2 inhibitor class was approved, and had continued to receive reports since that time. All drugs in the class were ...
Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...
While rare, diabetic ketoacidosis occurs overwhelmingly in patients taking SGLT2 inhibitors with type 2 diabetes, according to the analysis from 3 North Carolina medical schools. A data analysis in ...
(UPDATED) The use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is associated with more than a twofold increased risk of lower-limb amputations, as well as ...
Please provide your email address to receive an email when new articles are posted on . The incidence of diabetic ketoacidosis in patients with type 2 diabetes taking an SGLT2 inhibitor is no greater ...
Euglycemic diabetic ketoacidosis (EDKA) is characterised by the triad of metabolic acidosis with elevated anion gap, ketonaemia or ketonuria and near-normal blood glucose levels, typically below 200 ...
Please provide your email address to receive an email when new articles are posted on . MUNICH — Adults with type 2 diabetes and established CVD prescribed SGLT2 inhibitor therapy have a twofold ...
Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...